Not Yet RecruitingPhase 1ACTRN12621000868886

A Phase I Trial on The Bioavailability and Half-Life of Sublingually Administered Cannabis Products in Healthy People


Sponsor

Soma Group Limited

Enrollment

20 participants

Start Date

Jul 23, 2021

Study Type

Interventional

Conditions

Summary

This trial will investigate the single dose pharmacokinetics of two sublingually administered cannabis products, one CBD dominant the other THC dominant. This data will be used to inform dosing decisions in other trials. A secondary objective of this trial is to identify at what point do subjects begin to feel the intoxicating effects of these products and for how long they last.


Eligibility

Sex: Both males and femalesMin Age: 25 YearssMax Age: 75 Yearss

Exclusion Criteria11

  • Willing and able to give informed consent and be between 25 and 75 years of age
  • Willing and able to commit to a full day eight hour experiment session
  • Willing and able to attend therapy sessions once a month and complete other assessments when required
  • If applicable be willing and able to provide evidence of a negative pregnancy test taken no more than 72 hours prior to participating in the study
  • Any family or personal history of psychosis
  • Any history of cardiovascular disorders
  • Currently taking any other medications (other than birth control)
  • Must not be taking any herbal remedies e.g. Saint John's Wort
  • Any diagnosis of a DSM-V qualifying condition
  • Have any other current health condition that requires pharmaceutical treatment.
  • Participants must not have used any other cannabis product for at least one month prior to study entry or use any other cannabis product during the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Cohort 1: Single dose sublingually 2ml administration of a cannabis tincture containing 50mg Cannabidiol (CBD) and 1.9mg delta-9-Tetrahydrocannabinol (THC) per ml in solution with MCT oil. Participant

Cohort 1: Single dose sublingually 2ml administration of a cannabis tincture containing 50mg Cannabidiol (CBD) and 1.9mg delta-9-Tetrahydrocannabinol (THC) per ml in solution with MCT oil. Participants must hold the tincture under their tongue for 60 seconds before swallowing. Cohort 2: Single dose sublingually 2ml administration of a cannabis tincture containing 0mg CBD and 2.5mg THC per ml in solution with MCT oil. Participants must hold the tincture under their tongue for 60 seconds before swallowing.


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12621000868886


Related Trials